Sonen Capital LLC Sells 539 Shares of Johnson & Johnson (NYSE:JNJ)

Sonen Capital LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 23.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,777 shares of the company’s stock after selling 539 shares during the quarter. Sonen Capital LLC’s holdings in Johnson & Johnson were worth $279,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in JNJ. Massachusetts Wealth Management raised its stake in Johnson & Johnson by 4.2% in the third quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock valued at $2,508,000 after purchasing an additional 650 shares in the last quarter. Hennessy Advisors Inc. boosted its stake in Johnson & Johnson by 0.3% in the third quarter. Hennessy Advisors Inc. now owns 34,300 shares of the company’s stock valued at $5,342,000 after buying an additional 100 shares in the last quarter. SS&H Financial Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at approximately $3,164,000. White Lighthouse Investment Management Inc. boosted its position in Johnson & Johnson by 5.7% in the third quarter. White Lighthouse Investment Management Inc. now owns 8,497 shares of the company’s stock valued at $1,323,000 after buying an additional 459 shares in the last quarter. Finally, Harvey Investment Co. LLC grew its stake in shares of Johnson & Johnson by 9.3% during the third quarter. Harvey Investment Co. LLC now owns 218,505 shares of the company’s stock worth $34,032,000 after buying an additional 18,630 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 4.5 %

NYSE JNJ opened at $151.16 on Thursday. The stock has a market capitalization of $364.26 billion, a P/E ratio of 9.42, a P/E/G ratio of 2.42 and a beta of 0.53. The business has a 50 day simple moving average of $154.65 and a 200 day simple moving average of $155.11. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter last year, the firm posted $2.68 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date of this dividend is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 29.68%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on JNJ shares. Royal Bank of Canada reduced their price objective on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Raymond James lifted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Bank of America dropped their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.